The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
Mapping the Human Proteome
Gene Therapy Provides Hope to Hemophilia B Patients
Making Data-Driven Medicine a Reality
A Neuroscientist Turned Venture Investor Discusses TechBio Investing
A Nonprofit Seeks to Make Cell and Gene Therapies Affordable Worldwide
Disposing Toxic Proteins to Treat Neurodegenerative Diseases
Repurposing a Drug for Parasitic Infections as a Targeted GI Therapy
Targeting Chronic, Low-Grade Inflammation to Address Diseases of Aging
The Year in Biotech and What’s Ahead in 2022
Restoring the Guardian of the Genome to Fight Tumors
Advancing a Cell Therapy with the Potential to Cure HIV
Harnessing More Efficient Organisms to Reshore BioManufacutring
Using Digital Health Technology to Bring the Trial to the Patient
Using the Body’s Housecleaning Mechanism to Target Undruggable Proteins
Advocating for the Extension of Healthy Life
Using Donated Living Skin as an Alternative to Animal Testing
A Platform to Scale the Production of Personalized Cell Therapies
Developing Small Molecule Therapies to Target Proteins Only Biologics Have Been Able to Hit
Targeting Solid Tumors with Oncolytic Viruses
Reinventing the Discovery and Cell Line Development of Biotherapeutics
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind